0.80
+0.0013(+0.16%)
Currency In USD
| Previous Close | 0.8 |
| Open | 0.87 |
| Day High | 0.87 |
| Day Low | 0.79 |
| 52-Week High | 3.79 |
| 52-Week Low | 0.28 |
| Volume | 231,569 |
| Average Volume | 7.4M |
| Market Cap | 5.95M |
| PE | -0.18 |
| EPS | -4.43 |
| Moving Average 50 Days | 0.99 |
| Moving Average 200 Days | 0.84 |
| Change | 0 |
If you invested $1000 in Pasithea Therapeutics Corp. (KTTA) since IPO date, it would be worth $11.24 as of February 21, 2026 at a share price of $0.8. Whereas If you bought $1000 worth of Pasithea Therapeutics Corp. (KTTA) shares 3 years ago, it would be worth $70.8 as of February 21, 2026 at a share price of $0.8.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 17, 2026 12:01 PM GMT
– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –– Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage bi
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
GlobeNewswire Inc.
Jan 13, 2026 12:01 PM GMT
MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of neur
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
GlobeNewswire Inc.
Dec 02, 2025 12:00 PM GMT
Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Ma